LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a ...

PureTech Health has spied an opportunity to improve on Jazz Pharmaceuticals’ Epidiolex. Armed with its Glyph chemistry platform, the biotech has created an oral capsule formulation of cannabidiol (CBD ...

PureTech Health (PRTC) announces that the board of directors has appointed Robert Lyne as CEO, and as a member of the board of directors, ...

I’m honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I’ve seen ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

Robert Lyne has been named CEO of PureTech Health as the Boston biotech company seeks funding to spin out Celea Therapeutics ...

BOSTON, July 08, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of ...

PureTech Health has pieced together a wholly owned pipeline in recent years, picking up a prospect from Teva while taking ownership of Ariya Therapeutics and Alivio Therapeutics. With the expansion ...

PureTech Systems Inc., a provider of geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the integration of its patented PureActiv software with ...

PureTech Health has launched a subsidiary company – Celea Therapeutics – with the task of taking an experimental drug for idiopathic pulmonary fibrosis into late-stage clinical testing. Celea has been ...